A pilot clinical trial in Thailand is evaluating the safety of a turmeric and epigallocatechin-3-gallate (EGCG) emulgel, focusing on potential skin irritation and sensitization. Conducted by Kankanit Yeerong and colleagues from Chiang Mai University, the randomized, double-blind study involves 60 healthy participants aged 20-60 with specific skin phototypes. The study’s design includes tests for irritation and sensitization using validated protocols and will help inform larger-scale future trials for inflammatory skin diseases. Findings are awaited, with an emphasis on regulatory compliance for herbal topical therapies.

Source: BMJ Open